276 completed, 57 terminated, 48 unknown, 45 recruiting. 489 Phase 1, 149 Phase 2.
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LMT503 First-in-human SAD, MAD, and FE Study LMT503, Placebo - Inflammatory Bowel Disease, Colitis, Ulcerative | Phase 1 | Not yet recruiting | Lmito Therapeutics Inc. | 72 | 2027-03-01 | 2026-09-01 |
| Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis ATTO-1091, Placebo - Ulcerative Colitis (UC) | Phase 1 | Not yet recruiting | Attovia Therapeutics Inc | 96 | 2026-12-14 | 2026-09-15 |
| An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates Duvakitug - Ulcerative Colitis, Crohn's Disease | Phase 1 | Not yet recruiting | Sanofi | 25 | 2026-11-03 | 2026-11-06 |
| R-3750 in Patients With Crohn's Disease R-3750, Placebo - Crohn Disease (CD) | Phase 1 | Not yet recruiting | Rise Therapeutics LLC | 40 | 2026-11-01 | 2026-08-28 |
| Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers ICP-B161 (SC or IV), Placebo (SC or IV) - Inflammatory Bowel Disease(IBD) | Phase 1 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 88 | 2026-11-01 | 2026-11-03 |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers EQ504, EQ504 Placebo - Ulcerative Colitis | Phase 1 | Not yet recruiting | Equillium | 70 | 2026-10-01 | 2026-10-09 |
| Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants CM551, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) | Phase 1 | Not yet recruiting | Keymed Biosciences Co.Ltd | 48 | 2026-10-01 | 2026-10-28 |
| Gut Permeability and Microbiome in Preterm Infants measurement of intestinal permeability - Prematurity Complications | Phase 1 | Recruiting | University of Maryland, Baltimore | 150 | 2026-09-30 | 2026-10-05 |
| Phase 1b Clinical Study in Patients With Active Ulcerative Colitis TP317, Matching placebo - Ulcerative Colitis (UC) | Phase 1 | Not yet recruiting | Thetis Pharmaceuticals LLC | 24 | 2026-09-16 | 2026-09-22 |
| A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis Biological: HX15001 - Colitis, Ulcerative | Phase 1 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 32 | 2026-09-09 | 2026-08-17 |
| A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis Aletekitug - Colitis, Ulcerative | Phase 1 | Recruiting | GlaxoSmithKline | 16 | 2026-09-03 | 2026-11-05 |
| A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis Aletekitug (GSK1070806) - Colitis, Ulcerative | Phase 1 | Recruiting | GlaxoSmithKline | 8 | 2026-09-03 | 2026-10-28 |
| Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study Oxygen Gas for Inhalation, Standard of care - Inflammatory Bowel Disease (IBD), Crohn Disease | Phase 1 / Phase 2 | Not yet recruiting | University of British Columbia | 54 | 2026-09-01 | 2026-08-26 |
| A Phase 1 Study of ATORM-C in Patients With Crohn's Disease Autologous Adult Stem Cell-Derived Intestinal Organoid - Crohn's Diseases, Crohn's Disease | Phase 1 | Recruiting | ORGANOIDSCIENCES LTD. | 18 | 2026-09-01 | 2026-09-16 |
| Phase I Study of QLS1510 Tablets in Healthy Participants QLS1510 Tablets, QLS1510 placebo Tablets - Inflammatory Bowel Disease (IBD) | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 90 | 2026-08-30 | 2026-08-12 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis ONO-6414, Placebo - Ulcerative Colitis (UC) | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 90 | 2026-08-20 | 2026-09-09 |
| Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis Alpha-0261 - Ulcerative Colitis (UC) | Phase 1 | Not yet recruiting | The First Affiliated Hospital of Anhui Medical University | 10 | 2026-08-03 | 2026-08-04 |
| A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults AD-234, AD-2341, AD-2342 - Gastritis | Phase 1 | Not yet recruiting | Addpharma Inc. | 30 | 2026-08-01 | 2026-07-27 |
| Xylitol Use for Decolonization of C. Difficile in Patients With IBD Xylitol, Placebo - Inflammatory Bowel Diseases, Clostridioides Difficile Infection | Phase 1 | Not yet recruiting | Brigham and Women's Hospital | 99 | 2026-08-01 | 2026-02-25 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
Showing 20 of 489. Sign in to see all of them.
Colitis, Ulcerative (185) · Crohn Disease (167) · Inflammatory Bowel Diseases (115) · Dysentery, Bacillary (31) · Mucositis (21) · Enterocolitis, Necrotizing (16) · Colitis (15) · Eosinophilic Esophagitis (15) · Diarrhea (12) · Arthritis, Rheumatoid (10) · Arthritis, Psoriatic (8) · Gastritis (8) · Autoimmune Diseases (7) · Esophagitis, Peptic (7)
Digestive System Diseases (487) · Gastrointestinal Diseases (484) · Intestinal Diseases (432) · Inflammatory Bowel Diseases (240) · Colonic Diseases (200) · Colitis (178) · Pathological Conditions, Signs and Symptoms (56) · Infections (51) · Immune System Diseases (44) · Bacterial Infections and Mycoses (39) · Bacterial Infections (38) · Gram-Negative Bacterial Infections (32) · Enterobacteriaceae Infections (31) · Hemic and Lymphatic Diseases (29)
Fecal Microbiota Transplantation (21) · Mesalamine (10) · Saline Solution (6) · Cholecalciferol (5) · Infliximab (5) · Omeprazole (5) · Cyclophosphamide (4) · GSK1070806 (4) · Metronidazole (4) · Radiotherapy (4) · Vaccines (4) · Vancomycin (4) · YF 476 (4) · izencitinib (4) · vedolizumab (4)
GlaxoSmithKline (20) · National Institute of Allergy and Infectious Diseases (NIAID) (15) · Mayo Clinic (9) · Pfizer (8) · Stanford University (7) · AstraZeneca (6) · Bristol-Myers Squibb (6) · PATH (5) · Theravance Biopharma (5) · University Medical Center Groningen (5) · University of Alberta (5) · Anthony Lembo (4) · Brigham and Women's Hospital (4) · Janssen Research & Development, LLC (4) · Meir Medical Center (4)
United States (215) · United Kingdom (38) · China (35) · Canada (29) · Australia (28) · Netherlands (24) · Belgium (21) · Germany (21) · Poland (13) · Israel (12) · South Korea (12) · Spain (12) · France (11) · Georgia (11) · Moldova (11)
Amy Lightner, MD (6) · Bill Arana (3) · Subra Kugathasan, MD (3) · Yaron Ilan, MD (3) · Yinghong Wang (3)
PMID 17560413, PMID 22607579, PMID 27490698, PMID 28735965, PMID 34017343, PMID 36977960, PMID 37917289, PMID 38267790, PMID 38580386, PMID 17896890, PMID 19208097, PMID 19408340, PMID 19714757, PMID 20393336, PMID 20619378, PMID 20736987, PMID 20815703, PMID 21054494, PMID 21317177, PMID 22464259, PMID 22818551, PMID 22955430, PMID 23059643, PMID 23292233, PMID 23333143, PMID 23473061, PMID 23542823, PMID 23587979, PMID 23648372, PMID 23840001, PMID 24253285, PMID 24557009, PMID 24763133, PMID 24951828, PMID 25104129, PMID 25109413, PMID 25155966, PMID 25162366, PMID 25185797, PMID 25647155, PMID 25789989, PMID 25803642, PMID 25927273, PMID 26116801, PMID 26162850, PMID 26340878, PMID 26504182, PMID 26547399, PMID 26595549, PMID 26643677
2016 (5), 2017 (5), 2009 (3), 2015 (3), 2018 (3), 2014 (2), 2023 (2), 2025 (2), 1UL1RR025014-01 (1), 2019 (1), K24AI001610 (1), N01CN00035 (1), P30CA022453 (1), P30CA060553 (1), P30CA068485 (1)